Assertio Evaluates Alternatives as Acquisition Process Moves Forward
Assertio Holdings, has provided an important update regarding its ongoing acquisition process involving Garda Therapeutics, The announcement, distributed via Business Wire, outlines key developments tied to a previously disclosed agreement between the two companies and offers greater clarity on the next steps in the transaction timeline.
Overview of the Proposed Acquisition
Assertio confirmed that Garda Therapeutics intends to formally initiate a tender offer to acquire all outstanding shares of Assertio on April 29, 2026. This date is strategically set to follow the conclusion of a 20-day “window-shop” period, a provision that allows Assertio to evaluate alternative proposals that may provide greater value to its shareholders.
The acquisition agreement, originally announced on April 8, 2026, represents a significant milestone for both companies. Under the terms of the deal, Garda has agreed to purchase Assertio for $18.00 per share in cash. This equates to a total transaction value of approximately $125.1 million, reflecting a full buyout of the company’s outstanding equity.
In addition to the upfront cash payment, the agreement also includes a contingent value right (CVR). This component provides shareholders with the potential to receive additional financial benefits in the future, depending on the achievement of certain predefined milestones or performance targets.
Understanding the Tender Offer Process
A tender offer is a common mechanism used in mergers and acquisitions, particularly when one company seeks to acquire another by directly purchasing shares from its shareholders. In this case, Garda Therapeutics will extend an offer to Assertio shareholders, inviting them to sell their shares at the agreed-upon price of $18.00 per share.
Once the tender offer begins, shareholders will have the opportunity to decide whether to accept the offer and tender their shares. If a sufficient number of shares are tendered, Garda will be able to complete the acquisition and assume full ownership of Assertio.
The timing of the tender offer—immediately following the window-shop period—is significant. It indicates that the transaction is progressing according to plan, while still allowing room for potential competing bids during the interim period.
Details of the Window-Shop Provision
One of the key features of the Garda Agreement is the inclusion of a 20-day “window-shop” provision. This clause is designed to protect shareholder interests by allowing Assertio to actively engage with other potential buyers who may present a superior offer.
During this window-shop period, Assertio’s board of directors is permitted to:
- Solicit or consider alternative acquisition proposals
- Engage in discussions or negotiations with other interested parties
- Evaluate whether any competing offers provide greater value to shareholders
This provision ensures that the board fulfills its fiduciary duty to maximize shareholder value, rather than being locked into a single transaction without exploring other possibilities.
Breakup Fee and Superior Proposals
The agreement also outlines specific conditions under which Assertio may terminate its deal with Garda in favor of a superior proposal. If the company receives a more attractive offer during the window-shop period and decides to proceed with it, a reduced breakup fee would apply.
A breakup fee is a standard feature in acquisition agreements. It serves as compensation to the original bidder—in this case, Garda Therapeutics—for the time, effort, and resources invested in negotiating the deal. However, the reduced fee during the window-shop period is intentionally structured to avoid discouraging competing bids.
This balance is crucial. It provides Garda with a level of protection while still encouraging a competitive bidding environment that could ultimately benefit Assertio shareholders.
Financial Implications of the Deal
The proposed acquisition price of $18.00 per share represents the agreed valuation of Assertio at approximately $125.1 million. This figure reflects the company’s current market position, growth prospects, and strategic value to Garda Therapeutics.
The inclusion of a contingent value right adds another layer of financial consideration. While the upfront cash payment provides immediate value to shareholders, the CVR offers potential upside based on future performance metrics. These may include product development milestones, regulatory approvals, or revenue targets, though specific details are typically outlined in the full agreement.
For investors, this structure provides both certainty and opportunity—guaranteeing a baseline return while preserving the possibility of additional gains.
Strategic Rationale Behind the Acquisition
Although the announcement primarily focuses on procedural updates, the broader strategic rationale behind the acquisition is worth noting. Transactions like this often aim to create synergies between the acquiring and target companies.
For Garda Therapeutics, acquiring Assertio could offer:
- Access to established pharmaceutical assets and commercial infrastructure
- Expansion of its product portfolio
- Opportunities to leverage Assertio’s expertise in specific therapeutic areas
For Assertio, the deal provides shareholders with immediate liquidity and the potential for future upside through the CVR mechanism.
Market and Investor Considerations
The involvement of Nasdaq: ASRT highlights the public market dimension of this transaction. As a publicly traded company, Assertio is subject to regulatory requirements and investor scrutiny, making transparency and fairness critical throughout the process.
Investors will closely monitor several factors in the coming weeks, including:
- Whether any competing bids emerge during the window-shop period
- The final terms of the tender offer once formally launched
- Shareholder response and participation levels
The outcome of these factors will ultimately determine whether the acquisition proceeds as planned or takes a different direction.
With the window-shop period nearing its conclusion, the next major milestone will be the launch of the tender offer on April 29, 2026. At that point, shareholders will receive detailed information about the offer, including instructions on how to tender their shares.
If no superior proposals arise and the required number of shares is tendered, Garda Therapeutics will move forward with completing the acquisition. This would mark the culmination of the transaction process and the transition of Assertio into Garda’s ownership.
The update from Assertio Holdings provides a clear and structured view of where the acquisition process currently stands. The planned tender offer, combined with the recently concluded window-shop period, represents a critical phase in the transaction.
By incorporating mechanisms such as the window-shop provision and a reduced breakup fee, the agreement aims to balance deal certainty with shareholder value maximization. As the process unfolds, all eyes will be on whether competing offers emerge and how shareholders respond to Garda’s tender offer.
Ultimately, the transaction reflects a carefully negotiated agreement designed to align the interests of both companies and their stakeholders, while maintaining flexibility in a dynamic and competitive market environment.
About Assertio
Assertio is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. Our focus is on supporting patients by marketing products primarily in the oncology market.
